Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Recommendation of “Moderate Buy” by Brokerages

Denali Therapeutics Inc. (NASDAQ:DNLI) has been assigned a consensus rating of “Moderate Buy” from the nine analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $40.22.

DNLI has been the topic of several analyst reports. The Goldman Sachs Group lowered their target price on Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday, February 29th. Stifel Nicolaus lowered their price objective on shares of Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating on the stock in a research report on Wednesday, May 8th. Wedbush cut their price objective on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research report on Wednesday, May 8th. HC Wainwright reaffirmed a “buy” rating and issued a $95.00 target price on shares of Denali Therapeutics in a report on Wednesday, May 8th. Finally, UBS Group dropped their price target on shares of Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, April 9th.

Denali Therapeutics Price Performance

DNLI stock opened at $22.63 on Monday. The company has a market cap of $3.23 billion, a price-to-earnings ratio of -23.57 and a beta of 1.37. The company has a fifty day moving average price of $18.88 and a 200 day moving average price of $19.16. Denali Therapeutics has a 12 month low of $14.56 and a 12 month high of $31.03.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Tuesday, May 7th. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.01. Denali Therapeutics had a negative net margin of 36.51% and a negative return on equity of 11.46%. During the same period in the previous year, the business earned ($0.80) earnings per share. As a group, analysts anticipate that Denali Therapeutics will post -2.78 earnings per share for the current year.

Insider Activity at Denali Therapeutics

In other Denali Therapeutics news, Director Jennifer E. Cook sold 1,458 shares of the company’s stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $21.73, for a total transaction of $31,682.34. Following the transaction, the director now directly owns 20,038 shares in the company, valued at $435,425.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director Steve E. Krognes sold 92,500 shares of the firm’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $20.50, for a total value of $1,896,250.00. Following the completion of the transaction, the director now owns 47,341 shares in the company, valued at $970,490.50. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Jennifer E. Cook sold 1,458 shares of Denali Therapeutics stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $21.73, for a total value of $31,682.34. Following the transaction, the director now directly owns 20,038 shares of the company’s stock, valued at approximately $435,425.74. The disclosure for this sale can be found here. Insiders sold 95,624 shares of company stock worth $1,958,403 over the last 90 days. Company insiders own 7.90% of the company’s stock.

Hedge Funds Weigh In On Denali Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP grew its position in shares of Denali Therapeutics by 3.6% in the third quarter. Wellington Management Group LLP now owns 7,288,960 shares of the company’s stock valued at $150,371,000 after purchasing an additional 250,784 shares during the last quarter. Edmond DE Rothschild Holding S.A. increased its position in Denali Therapeutics by 65.9% during the fourth quarter. Edmond DE Rothschild Holding S.A. now owns 165,680 shares of the company’s stock worth $3,555,000 after buying an additional 65,800 shares in the last quarter. Pathway Capital Management LP acquired a new position in shares of Denali Therapeutics in the fourth quarter worth $1,490,000. Gotham Asset Management LLC purchased a new stake in shares of Denali Therapeutics in the third quarter valued at $400,000. Finally, Eventide Asset Management LLC lifted its position in shares of Denali Therapeutics by 98.4% in the third quarter. Eventide Asset Management LLC now owns 621,850 shares of the company’s stock valued at $12,829,000 after acquiring an additional 308,443 shares in the last quarter. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.